Novo Nordisk could lose millions on discount dispute in US
The first round of a legal strife with US authorities concerning drug discounts for vulnerable Americans did not end favorably for Novo Nordisk. If the Danish giant keeps losing, the case could end up costing DKK 2bn (USD 307.3m) in lost revenue.
by benjamin werner christensen, translated by daniel pedersen
A strife concerning drugs for vulnerable or uninsured Americans could end up costing Danish pharmaceutical giant Novo Nordisk many millions of dollars.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
-go.jpg)
Eli Lilly sues HHS in strife over discounted drugs
For subscribers
